6-amino-1-((2R,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)-1H-thieno[2,3-d]imidazole-5-carboxamide | 1250866-31-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-amino-1-((2R,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)-1H-thieno[2,3-d]imidazole-5-carboxamide
• CAS: 1250866-31-9
• 化学式: C₃₃H₃₄N₄O₅S
• 分子量: 598.723
• InChiKey: ZYKYVRQYCDINQU-QDDJPOCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.45
• 重原子数：
  43.0
• 可旋转键数：
  12.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  123.85
• 氢给体数：
  2.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  二硫化碳 、 6-amino-1-((2R,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)-1H-thieno[2,3-d]imidazole-5-carboxamide 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Tricyclic 2′-C-Modified Nucleosides as Potential Anti-HCV Therapeutics

  摘要：

  Promising biological activity in a number of therapeutic areas has been reported for both tricyclic nucleosides and 2'-modified nucleosides. In particular, disubstitution at the C-2' position of nucleosides has resulted in significant activity against the hepatitis C virus (HCV). Combining this with the observation that tricyclic nucleosides developed in our laboratory have been shown to inhibit the RNA-dependent RNA polymerase NS5B led to the design of a series of 2'-modified tricyclic nucleosides. Details of the synthesis, structural characterization, and preliminary biological results are reported.

  DOI：

  10.1021/ol101482h
• 作为产物：
  描述：

  在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以300 mg的产率得到6-amino-1-((2R,3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-3-methyltetrahydrofuran-2-yl)-1H-thieno[2,3-d]imidazole-5-carboxamide
  参考文献：
  名称：

  Tricyclic 2′-C-Modified Nucleosides as Potential Anti-HCV Therapeutics

  摘要：

  Promising biological activity in a number of therapeutic areas has been reported for both tricyclic nucleosides and 2'-modified nucleosides. In particular, disubstitution at the C-2' position of nucleosides has resulted in significant activity against the hepatitis C virus (HCV). Combining this with the observation that tricyclic nucleosides developed in our laboratory have been shown to inhibit the RNA-dependent RNA polymerase NS5B led to the design of a series of 2'-modified tricyclic nucleosides. Details of the synthesis, structural characterization, and preliminary biological results are reported.

  DOI：

  10.1021/ol101482h